Drugs / LVGN7409
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05075993 | Nov 2021 → Feb 2027 expected | esophageal cancer, gastric cancer, head and neck carcinoma, hepatocellular carcinoma +4 | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05152212 | Sep 2021 → Dec 2023 | cancer | Lyvgen Biopharma Holdings Limited | Completed | No outcome recorded |
| Phase 1 | NCT04635995 | Dec 2020 → Dec 2025 | cancer | Lyvgen Biopharma Holdings Limited | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06159621 Comparator | Jul 2024 → Mar 2028 expected | head and neck squamous cell carcinoma | University of Pennsylvania | Active not recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-11-27 | Lyvgen Biopharma Holdings Limited | Lyvgen Announces Phase 2 Clinical Collaboration with Bristol Myers Squibb to Evaluate LVGN7409 in Combination with Nivolumab in Non-Small Cell Lung Cancer Patients lyvgen.com ↗ |
| 2021-01-26 | Lyvgen Biopharma Holdings Limited | Lyvgen Announces First in Human Dosing of LVGN7409 CD40 Agonist Monoclonal Antibody in a Phase 1 Clinical Trial for the Treatment of Advanced or Metastatic Malignancy in the US lyvgen.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LVGN7409 | “This protocol proposes to study the safety and immunological effects of LVGN7409, a CD40 agonistic antibody, when administered in combination with PD-1 inhibition prior to...” NCT06159621 ↗ |
| Action | Activate | “acts as an agonist against CD40” NCT04635995 ↗ |
| Modality | Monoclonal antibody | “humanized monoclonal antibody” NCT04635995 ↗ |
| Route | Intravenous | “IV infusion” NCT04635995 ↗ |
| Target | CD40 | “specifically binds to CD40” NCT04635995 ↗ |